Unique ID issued by UMIN | UMIN000029433 |
---|---|
Receipt number | R000029940 |
Scientific Title | Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancer |
Date of disclosure of the study information | 2017/10/05 |
Last modified on | 2021/04/19 16:48:55 |
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancer
Neoadjuvant chemotherapy for BRCAness
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancer
Neoadjuvant chemotherapy for BRCAness
Japan |
Breast cancer
Breast surgery |
Malignancy
NO
The efficacy of anthracycline based chemotherapy is investigated for BRCAness
homologous recombination deficiency cases in triple negative breast cancer patients.
Efficacy
pathologic complete response(pCR)
Interventional
Parallel
Non-randomized
Open -no one is blinded
Active
2
Prevention
Medicine |
Patients who have obtained consent from tis study will start neoadjuvant chemotherapy with the following 3 anti-cancer drugs every 3 weeks for a total of 4 cycles.
Fluorouracil 500mg/m2 Epirubicin 100mg/m2 Cyclophosphamide 100m/m2
BRCAness is examined and cases with non-BRCAness will be taken Taxan every 3 weeks, for a total of 4 cycles.
Cases with BRCAness will undergo surgery without adding Taxan. If pCR is not obtained, Taxan will be given.
20 | years-old | <= |
75 | years-old | >= |
Female
1.Patients with primary breast cancer who indicates the neoadjuvant chemotherapy from stage 1-3
2.PS 0-1
3.normal cardiac function
4.clinical examination is normal
1.Patients who have been administered moderate doses of anti-cancer drugs.
2.Patients who have been undergone gastrointestinal surgery
3.Active double cancers
4.Pregnant, lactating, possible pregnancy, having oral contraceptive
5.Patients who the investigator judged unsuitable for this trial
70
1st name | Takashi |
Middle name | |
Last name | Ishikawa |
Tokyo medical university hospital
breast oncology
1600023
6-1-1 Nishishinnjyuku Shinjyuku-ku Tokyo
0333516141
tishik55@gmail.com
1st name | Saeko |
Middle name | |
Last name | Teraoka |
Tokyo medical university hospital
breast oncology
1600023
6-1-1 Nishishinnjyuku Shinjyuku-ku Tokyo
0333516141
s_teraoka0809@yahoo.co.jp
Tokyo medical university
Tokyo medical university cancer institute.
Self funding
FALCO biosystems
TokyoMedicalUniversityHospital
6-7-1 Nishishinnjyuku Shinjyuku-ku Tokyo
0333426111
s_teraoka0809@yahoo.co.jp
NO
2017 | Year | 10 | Month | 05 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 05 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2017 | Year | 10 | Month | 05 | Day |
2021 | Year | 04 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029940
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |